Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
  • A61K33/26—Iron; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
  • A61K33/30—Zinc; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
  • A61K33/34—Copper; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
  • A61L26/0061—Use of materials characterised by their function or physical properties
  • A61L26/0066—Medicaments; Biocides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/02—Local antiseptics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
  • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents

Definitions

• the invention relates to stabilized antiseptic preparations for topical formulations which can be used in the human and veterinary field for treatments in the wound area, for the microbiological rehabilitation of skin surfaces, for the disinfection of skin and hands or for wound and bladder irrigation.
• EP 2522223 combined disinfectants and decontaminants with increased efficacy are disclosed which contain at least one vitamin, at least one metal ion, at least one surface-active compound and at least one antimicrobial active ingredient from the group of quaternary ammonium compounds, and optionally further antimicrobial active substances. These agents can be used for decontamination or disinfection of busy and inanimate surfaces.
• EP 1881763 describes decontamination solutions and their use for denaturing, modifying, degrading, solubilizing and removing proteins, nucleic acid molecules and microorganisms which consist of at least one vitamin, at least one metal ion and at least one surface-active compound.
• EP 2170398 discloses uses as a therapeutic agent or disinfectant.
• the object of the invention is to provide an antiseptic preparation or composition which does not have the above-mentioned and other disadvantages.
• an antiseptic preparation should be stabilized for a time sufficient to maintain the efficacy required for the intended use.
• One aspect of the invention relates to stabilized antiseptic preparations.
• Stabilized antiseptic preparations comprise at least one vitamin, and / or at least one metal ion, and / or at least one surface-active compound, and / or at least one gelling agent and / or at least one antimicrobial agent from the group of the quaternary ammonium compounds and / or at least one further antimicrobial agent selected from the group consisting of: organic and inorganic acids or their salts, esters, amides, aliphatic or aromatic monoaldehydes or dialdehydes, guanidines, pyridines or pyrimidines.
• a preparation according to the invention has a pH of the mixture in the range from 0.5 to 8.5.
• vitamins their salts or acidic derivatives
• at least one compound selected from the group consisting of vitamins A, B, C and E are advantageous.
• the metal ions originate from the metals of the 4th period and the subgroups I, II or VIII of the periodic system of the elements, particularly advantageously iron, copper and zinc.
• the metals are advantageously in the form of their salts with acids or bases, as oxides or organometallic compounds.
• At least one compound selected from the group of anionic, nonionic, amphoteric or cationic surfactants or suitable mixtures with one another or with one another is advantageously present as the surface-active substance.
• the gelling agent is advantageously selected from the group of polysaccharides, preferably agarose, carrageenan, pectin, xanthan, alginic acid and alginates, silicon dioxide, polyvinyl pyrrolidones, polyvinyl alcohols, polymethacrylates, preferably poly (hydroxymethacrylates) or poly (N-isopropyl methacrylates) or polyacrylic acids, or suitable mixtures thereof.
• the further antimicrobial active ingredient is one or more aliphatic or aromatic organic acid or an inorganic acid or its salt, ester or amide.
• This further antimicrobial active ingredient is particularly advantageously selected from the group consisting of formic acid, acetic acid, bromoacetic acid, glycolic acid, propionic acid, glyoxylic acid, lactic acid, citric acid, tartaric acid, malonic acid, maleic acid, fumaric acid, pyrrolidonecarboxylic acid, sorbic acid, undecylenic acid, undecynic acid, benzoic acid, hydro xybenzoic acid, salicylic acid, dehydroacetic acid, 4-hydroxybenzoic acid esters, dimethyl carbonate, chloroacetamide, 2-chloro-N- (hydroxymethyl) acetamide, salicylanilide, phosphoric acid, sulfuric acid, hydrochloric acid, boric acid, sulfurous acid, nitric acid and / or carbon
• the vitamin is advantageously contained in amounts of from 0.1 mM to 1000 mM.
• the metal ion is advantageously contained in amounts of 0.01 mM to 100 mM.
• the surface-active substance is advantageously contained in amounts of from 0.01% to 35% by weight of the preparation.
• the gelling agent is advantageously contained in amounts of 0.25% to 4.5%, preferably 0.5% to 3.5%, particularly preferably 0.75% to 2.5%, based on the preparation.
• a preparation according to the invention may advantageously be formulated in a topical, dermatological or cosmetic formulation, e.g. Gel, lotion, solution, cream, ointment, powder, microspheres, liposomes, foam, stick, conditioner, spray, etc., be incorporated.
• a topical, dermatological or cosmetic formulation e.g. Gel, lotion, solution, cream, ointment, powder, microspheres, liposomes, foam, stick, conditioner, spray, etc.
• a preparation according to the invention can advantageously also be applied to a carrier material.
• Another aspect of the invention relates to the use of stabilized antiseptic preparations according to the invention, in particular stabilized antiseptic preparations as mentioned above for use in the treatment of wounds in the human and veterinary field, and / or for the microbiological remediation of skin surfaces.
• the preparation is used in conjunction with a compress or wound dressing, preferably a dressing, a plaster and / or other wound covering.
• the preparation is used in a foamed form in such a use.
• the preparation can advantageously be used as a wound irrigation solution or moisture constituent of a wound dressing or as a rinsing solution or moisture constituent for the microbiological refurbishment of skin areas.
• a further advantageous variant of an inventive use of a stabilized antiseptic preparation relates to a stabilized antiseptic composition according to the invention. preparation for use in the prevention and / or treatment of pathological conditions in the genitourinary area.
• the preparation is used as a bubble rinse.
• Yet another advantageous variant of a stabilized antiseptic preparation according to the invention relates to a stabilized antiseptic preparation according to the invention for use in microbiological rehabilitation of the urogenital region.
• the preparation is applied in a topical formulation in the urogenital region, preferably in the area between the anus and the urethra, or it is applied to a support, e.g. Panty liner (Panty Liner), applied and placed in the area between the anus and urethra, possibly interlabial.
• a topical formulation in the urogenital region, preferably in the area between the anus and the urethra, or it is applied to a support, e.g. Panty liner (Panty Liner), applied and placed in the area between the anus and urethra, possibly interlabial.
• Panty liner Panty Liner
• Yet another advantageous variant of an inventive use of a stabilized antiseptic preparation relates to a stabilized antiseptic preparation according to the invention for use for skin and hand disinfection.
• Figure 1 shows the experimentally determined stabilizing effect of agarose as
• Figure 2 shows the release of the antiseptic agent for various layer thicknesses and gel formers.
• antiseptic formulations are obtained by adding a gelling agent, e.g. Polysaccharides, alginates, polyvinyl alcohols, etc. can be stabilized.
• a gelling agent e.g. Polysaccharides, alginates, polyvinyl alcohols, etc.
• Preparations according to the invention comprise at least one synergistic mixture of at least one vitamin, at least one metal ion, at least one surface-active compound and at least one gelling agent.
• at least one antimicrobial agent from the group of quaternary ammonium compounds and / or at least one other antimicrobial agent selected from the group consisting of organic and inorganic acids or their salts, esters, amides, aliphatic or aromatic monoaldehydes or dialdehydes, guanidines, pyridines or Pyrimidines be present.
• the pH of preparations according to the invention is in the range from 0.5 to 8.5, in particular from 1 to 7, preferably 2 to 6, particularly preferably 2 to 4.5.
• the pH Value may be with organic acids such as formic acid, acetic acid, propionic acid, citric acid, tartaric acid, malic acid, inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, etc. or buffer systems such as citrate, phosphate, tris (hydroxymehtyl) aminomethane (Tris), Succinate, carbonate, borate, oxalate, glycine, tartrate, acetate buffer, etc. or suitable mixtures thereof.
• the antiseptic activity is given over the entire specified pH range.
• the vitamins in preparations according to the invention are selected from the group of vitamins A, B, C and E, and are present as vitamins, their salts and / or acid derivatives. Mixtures of several vitamins can be used. Preferably, vitamin C, riboflavin and niacin are used.
• the amounts of the vitamins are preferably between 0.1 mM and 1000 mM, in particular between 1 mM and 500 mM, preferably between 1 mM and 300 mM, and very particularly preferably between 1 mM and 100 mM.
• the preparations according to the invention contain metal ions of the metals of the 4th period and transition groups I, II or VIII of the Periodic Table of the Elements.
• the ions may be present in the form of their salts with acids or bases, as oxides or organometallic compounds. Either single metal ions or mixtures of several ions are used.
• ions of the metals iron, cobalt, nickel, copper or zinc are contained in amounts of from 0.01 mM to 100 mM, preferably from 0.4 mM to 50 mM, in particular from 1 mM to 30 mM, very particularly preferably from 1 mM to 10 mM ,
• surfactants are required in the mixture. These are selected from the group of anionic, nonionic, amphoteric or cationic surfactants. These are, for example, alkyl ether sulfates, alkyl and / or aryl sulfonates, alkyl sulfates, olefin sulfonates, amines photensides, betaines, alkylamidoalkylamines, alkyl-substituted amino acids and / or imino acids, acylated amino acids, sugar surfactants, quaternary ammonium compounds, etc.
• the surfactants are used either individually or in suitable mixtures with one another.
• the typical amounts are between 0.1% by weight and 35% by weight, preferably 0.2% by weight and 30% by weight, particularly preferably 0.5% by weight and 20% by weight. , most preferably 0.5 wt .-% and 15 wt .-%.
• the gelling agents used are polysaccharides, preferably agarose, carrageenan, pectin, xanthan, alginic acid and alginates, silicon dioxide, polyvinylpyrrolidones, polyvinyl alcohols, polymethacrylates, preferably poly (hydroxymethacrylates) or poly (N-isopropyl methacrylates) or polyacrylic acids, or suitable mixtures thereof , Agarose and carrageenan are particularly preferred.
• the gelling agents are used in amounts of from 0.25% to 4.5%, preferably 0.5% to 3.5%, particularly preferably 0.75% to 2.5%, based on the preparation.
• alginate and hyaluronic acid are less suitable. Chitosan in turn can not be gelled in the acidic pH range ⁇ 5.
• antiseptic preparations For the production of antiseptic preparations according to the invention, it is advantageous first to prepare the gel and then to incorporate the other components of the antiseptic preparation so that the stabilized antiseptic preparation is finally obtained.
• the preparations according to the invention may contain further antimicrobial agents selected from the group of quaternary ammonium compounds, e.g. Benzalkonium chloride, procuronium chloride, trimethylundecylammonium chloride, benzethonium chloride, etc.
• quaternary ammonium compounds e.g. Benzalkonium chloride, procuronium chloride, trimethylundecylammonium chloride, benzethonium chloride, etc.
• antimicrobial agents aliphatic or aromatic organic acids or inorganic acids or their salts, esters or amides can be incorporated, these antimicrobial agents are selected from the group consisting of formic acid, acetic acid, bromoacetic acid, glycolic acid, propionic acid, glyoxylic acid, lactic acid, citric acid, Tartaric acid, malonic acid, maleic acid, fumaric acid, pyrrolidonecarboxylic acid, sorbic acid, undecylenic acid, undecynic acid, benzoic acid, hydroxybenzoic acid, salicylic acid, dehydroacetic acid, 4- Hydroxybenzoic acid esters, dimethyl carbonate, chloroacetamide, 2-chloro-N- (hydroxymethyl) acetamide, salicylanilide, phosphoric acid, sulfuric acid, hydrochloric acid, boric acid, sulfurous acid, nitric acid and / or carbonic acid or mixtures thereof.
• topically in this context means that the formulations in the human and veterinary field have living surfaces on the body, e.g. Skin, hair, etc. and / or within the body, e.g. Bladder, oral cavity, vagina, etc. are brought into contact.
• These formulations may e.g. Gel, lotion, solution, cream, ointment, powder, microspheres, liposomes, foam, stick, conditioner, spray, etc.
• the antiseptic preparations either as such and / or the mentioned formulations are applied to a carrier material.
• a carrier material may e.g. Include gauze, compresses, wound dressings, patches, panty liners, etc.
• the formulations may be applied directly to the living surface, e.g. Skin, wound, etc. are applied and then covered with a compress, wound dressing, bandage, patch or other wound cover.
• bio-or co-adhesive substances may be added to the preparations and / or formulations.
• Preparations or formulations according to the invention can also be used as such for wound treatment. In certain cases, it is advantageous to use the preparations in a foamed form, for example to supply pain-sensitive wounds.
• preparations and / or formulations according to the invention can be used as wound irrigation solution or moisture constituent of a wound dressing or as rinsing solution or moisture component.
• the preparations or formulations according to the invention are used in the area between the anus and urethra, these pathological conditions can be prevented or and / and / or treated.
• the preparations are applied as such and / or in the form of formulations such as gel, lotion, solution, cream, ointment, powder, microspheres, liposomes, foam, stick, rinse, spray, etc. in this area.
• the urogenital area is microbiologically rehabilitated.
• the formulations or formulations are applied to a panty liner and, as usual, placed in the urogenital region, the panty liner possibly covering the area including the anus and pubic area, or being placed between the labia minora.
• the preparations are used as bladder rinsing, wherein they remediate the bubble microbiologically.
• Figure 1 shows the example of agarose the stabilizing effect of various gelling agent concentrations on an antiseptic solution containing ascorbic acid, citric acid, tartaric acid, sodium lauryl sulfate and cupric chloride.
• the solutions discolor rapidly, i. they lose their bluish color, become brownish and at the same time lose their effectiveness. The bluish color can therefore be considered as an indicator of stability and effectiveness.
• gels with different gel former concentrations were stored for 18 days at different temperatures. The blue color fraction was subsequently determined colorimetrically.
• the reference used was a preparation which was stored under protective gas (argon) at 23 ° C.
• the figure clearly shows the stabilizing effect of the gel formers. Especially at higher temperatures, for example at body temperature (37 ° C), the relative stabilization is significant. Thus, with a gelling agent concentration of already 0.5% by weight of agarose, the remaining concentration is six times higher than without stabilization.
• the concentration of copper in the surrounding medium over time was measured as a leading indicator.
• the release kinetics could be determined, as shown in Figure 2, for various gelling agents (agarose, carrageenan), various concentrations in wt.%, And different layer thicknesses (3, 6 and 12 mm). It can be clearly seen that the release can be controlled both by the gel concentration and by the layer thickness. This is important for the wound care, the microbiological rehabilitation of the urogenital area and especially the skin and hand disinfection.
• the present invention is not limited in scope to the specific embodiments described herein.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Inorganic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Dermatology (AREA)
• Materials Engineering (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=57233384

Family Applications (1)

Country Status (4)

Families Citing this family (3)

Family Cites Families (9)

• 2016
  • 2016-09-20 WO PCT/EP2016/072251 patent/WO2017055135A1/de active Application Filing
  • 2016-09-20 RU RU2018110624A patent/RU2743529C1/ru active
  • 2016-09-20 EP EP16790888.8A patent/EP3355860A1/de active Pending
  • 2016-09-20 US US15/763,838 patent/US20190000876A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events